Showing 4561-4570 of 8860 results for "".
- Senté Launches Cysteamine HSA Pigment & Tone Correctorhttps://practicaldermatology.com/news/sente-launches-cysteamine-hsa-pigment-tone-corrector/2461301/Cysteamine HSA Pigment & Tone Corrector from Senté has launched to safely and effectively target pigmentation in all skin tones. The hydroquinone-free formula is safe for long-term use and formulated for all skin types, including dry or sensitive skin.
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- La Roche-Posay, American Cancer Society Partner to Improve Patient and Caregiver Quality of Lifehttps://practicaldermatology.com/news/la-roche-posay-american-cancer-partner-to-improve-patient-and-caregiver-quality-of-life/2461299/La Roche-Posay US is joining forces with the American Cancer Society (ACS) to further the support of cancer patients, survivors, caregivers, and the oncology community as well as raise awareness of cancer treatments' skin side effects. Since 1905, La Roche-Posay has been committed to improvin
- Alma Launches the Alma Hybrid and Alma TED Systems in Canadahttps://practicaldermatology.com/news/alma-launches-the-alma-hybrid-and-alma-ted-systems-in-canada/2461298/Alma Hybrid and Alma TED systems are now commercially available in Canada, the company reports. Alma Hybrid, the first laser platform to include an ablative 10,600 nm (CO2) laser and a non-ablative 1570 nm laser for skin resurfacing that offers a comprehensive solution to utilize each b
- Aesthetics Biomedical Inc. Receives Third U.S. Patent for “Biological Preserving Composition and Methods of Use” for SoME Skincare Product Linehttps://practicaldermatology.com/news/aesthetics-biomedical-inc-receives-third-us-patent-for-biological-preserving-composition-and-methods-of-use-for-its-some-skincare-product-line/2461296/Aesthetics Biomedical Inc. scored its third U.S. patent for “biological preserving composition and methods of use” for its SoME skincare product line. The patent covers topical compositions for combining biologics with skincare preserving the exclusivity of SoME Skincar
- National Academies Call on EPA to Study Sunscreen Effects on Aquatic Ecosystemshttps://practicaldermatology.com/news/national-academies-calls-on-epa-to-study-sunscreen-effects-on-aquatic-ecosystems/2461295/Due to concern about the deleterious effect of ultraviolet filters on aquatic ecosystems and the species that live within them, including coral, the National Academies of Sciences, Engineering, and Medicine is urging the Environmental Protection Agency (EPA) to carry out
- Expert FDA Panel Recommends Skin Lesion Analyzers and Apps for Skin Cancer Detection Keep Class III Statushttps://practicaldermatology.com/news/expert-fda-panel-recommends-skin-lesion-analyzers-and-apps-for-skin-cancer-detection-keep-class-iii-status/2461293/The FDA held a meeting with the Medical Devices Advisory Committee in late July to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for mo
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formula
- Arcutis Completes Enrollment in Pivotal Phase 3 Roflumilast AD Trialhttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-pivotal-phase-3-roflumilast-ad-trial/2461290/Arcutis Biotherapeutics, Inc. has completed enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria